Stay updated on Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Sign up to get notified when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.

Latest updates to the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page
- Check2 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check52 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a clinical study on surufatinib versus Capecitabine for biliary tract cancer, and the addition of a new version revision number. The study's inclusion and exclusion criteria have also been altered, impacting the understanding of the study's parameters.SummaryDifference52%
- Check73 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.